Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.40 |
| ▸ | CTSK | P43235 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL887437 | 0.83 | CTSS (0.46) | CTSSCTSKATMMAPTNPC1 | |
| SCHEMBL10100475 | 0.81 | SYK (0.50) | CTSSCTSKATMCTSLCTSB | |
| SCHEMBL13168624 | 0.81 | CTSK (0.51) | CTSSCTSKATMCTSLCTSB | |
| SCHEMBL887458 | 0.81 | CTSK (0.51) | CTSSCTSKATMCTSLCTSB | |
| SCHEMBL14327800 | 0.81 | CTSK (0.51) | CTSSCTSKATMCTSLCTSB | |
| SCHEMBL15289107 | 0.80 | GABRB1 (0.42) | CTSSCTSKATMCTSLCTSB | |
| SCHEMBL13168658 | 0.77 | NPC1 (0.52) | CTSSCTSKATMCTSLCTSB | |
| SCHEMBL25238924 | 0.77 | CTSS (0.50) | CTSSCTSKATMCTSLCTSB | |
| SCHEMBL15270603 | 0.77 | CTSS (0.47) | CTSSCTSKATMCTSLCTSB | |
| SCHEMBL15270465 | 0.77 | CTSS (0.50) | CTSSCTSKATMCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902207-B2 | Process for production of amines | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20070142639-A1 | Process for production of amines | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142639-A1 | Process for production of amines | SMS, CCNT1, PEAK1 | CTSS 4383/4885CTSK 4517/4885ATM 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.